Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.36 USD | +9.75% | +12.52% | +12.52% |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 08 | Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views | MT |
Business Summary
Number of employees: 58
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 196 | 100.0 % | 131 | 100.0 % | -33.09% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 196 | 100.0 % | 131 | 100.0 % | -33.09% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 | |
Andrew Reardon
LAW | General Counsel | 49 | 21-12-31 |
Corporate Officer/Principal | - | Feb. 19 | |
Karen Reeves
PRN | Corporate Officer/Principal | - | Feb. 19 |
Human Resources Officer | - | 94-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Jason Aryeh
BRD | Director/Board Member | 56 | 06-09-26 |
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Nancy Ryan Gray
BRD | Director/Board Member | 64 | 17-08-17 |
Director/Board Member | 55 | 23-09-25 | |
Jason Haas
BRD | Director/Board Member | 56 | 22-06-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,958,354 | 17,519,555 ( 97.56 %) | 0 | 97.56 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
3,616,077 | 3.31% | 296,518,314 $ |
Company contact information
Ligand Pharmaceuticals, Inc.
555 Heritage Drive Suite 200
33458, Jupiter
+858 550 7500
http://www.ligand.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.52% | 1.44B | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.70% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- LGND Stock
- Company Ligand Pharmaceuticals Incorporated